AstraZeneca is acquiring Alexion Pharmaceuticals for $39 billion, with the deal expected to close in the third quarter of 2021.

Researchers at Johns Hopkins Medicine identified a protein – known as factor D – that appears essential to the inflammatory process of SARS-CoV-2, the virus that causes Covid-19.